Connect with us

Technology

S&P 500 Q1 2024 Buybacks Increase 8.1% from Q4 2023; 12-month Expenditure Declines 4.8% from Previous Year, Earnings Per Share Impact Reverses Showing First Gain in Five Quarters; Buybacks Tax Results in a 0.47% Reduction in Q1 Operating Earnings and 0.41% Reduction in 12-month Earnings

Published

5 months ago

on

S&P 500 Q1 2024 buybacks were $236.8 billion, up 8.1% from Q4 2023’s $219.1 billion and up 9.9% from Q1 2023’s $215.5 billionThe 12-month March 2024 expenditure of $816.5 billion was down 4.8% from the prior 12-month expenditure of $857.2 billion Consumer Staples increased spending by 32.7%, as Consumer Discretionary reduced spending by 44.1%; Information Technology ticked up 1.8% and Health Care jumped 93.5% The net buyback 1% tax reduced Q1 2024 operating earnings by 0.47% and As Reported GAAP by 0.54%

NEW YORK, June 17, 2024 /PRNewswire/ — S&P Dow Jones Indices (S&P DJI) today announced the preliminary S&P 500® stock buybacks or share repurchases data for Q1 2024.

Historical data on S&P 500 buybacks is available at www.spdji.com/indices/equity/sp-500.

Key Takeaways:

Q1 2024 share repurchases were $236.8 billion, up 8.1% from Q4 2023’s $219.1 billion expenditure, and up 9.9% from Q1 2023’s $215.5 billion.For the 12-months ending March 2024, buybacks were $816.5 billion, down from $867.2 billion for the prior 12-month March 2023 period; the 12-month peak was in June 2022 with $1.005 trillion.352 companies reported buybacks of at least $5 million for the quarter, up from 313 in Q4 2023 and down from 358 in Q1 2023; 380 companies did some buybacks for the quarter, up from 373 in Q4 2023 and down from 390 in Q1 2023; 419 companies did some buybacks in the last 12-month period, down from 432 in the prior 12-month period.Buybacks concentration declined but remained top heavy, with the top 20 S&P 500 companies accounting for 50.9% of Q1 2024 buybacks, down from Q4 2023’s 54.1%, but above the historical average of 47.5%, and above the pre-COVID historical average of 44.5%.13.3% of companies reduced share counts used for earnings per share (EPS) by at least 4% year-over-year, up from Q4 2023’s 12.6% and down from Q1 2023’s 18.5%, it was the first EPS impact increase since Q3 2022; for Q1 2024 196 issues increased their shares used for EPS over Q4 2023, and 255 reduced them.S&P 500 Q1 2024 dividends decreased 1.6% to $151.6 billion from the prior Q4 2023 record of $154.1 billion and were 3.3% greater than the $146.8 billion in Q1 2023. For the 12-month’s ending March 2024, dividends set a record $593.1 billion payments, up 3.4% on an aggregate basis from the prior 12-month March 2023’s $573.7 billion.Total shareholders return of buybacks and dividends increased to $388.4 billion in Q1 2024, up 4.1% from Q4 2023’s $373.2 billion and up 7.2% from Q1 2023’s $362.3 billion. Total shareholder returns for the 12-months ending March 2024 decreased 1.5% to $1.410 trillion from the prior 12-month March 2023’s $1.431 trillion.The 1% tax on net buybacks, which started in 2023, reduced the Q1 2024 S&P 500 operating earnings by 0.47%, up from Q4 2023’s 0.44% impact, and As Reported GAAP earnings by 0.54% up from the prior 0.50%; for the 12-month March 2024 period they reduced earnings 0.41% for operating and 0.46% for As Reported.

“The share count impact on EPS increased for the first time after five consecutive quarters of declines as companies increased their overall buyback expenditure by 8%, which countered the impact of both share issuance and employee options being exercised. While buybacks supported share price, 13.3% of the issues saw a significant increase (of at least 4%) in their EPS due to share count reduction, compared to 18.5% in Q1 2023. For Q1 2024, more issues did buybacks and spent more. While the 13.3% remains lower than the 17.5% average and pales compared to the almost 25% rate posted in Q1 2019, the increase comes after five quarters of declines, and hints to a forward upswing. Companies with strong cashflows continued to aggressively do buybacks, as the top 20 issues accounted for 50.9% of the buybacks in Q1 2024,” said Howard Silverblatt, Senior Index Analyst at S&P Dow Jones Indices.

“Given the market’s current expectations for interest rates to decline later in the year and the continued uncertainty over geopolitical and domestic issues, companies may be shy to finance buybacks going forward as discretionary buybacks, which reduce share count, may need to be financed from ongoing operations. Top-tier cash-flow issues however are seen as continuing their buybacks and positively impacting their EPS.”

1% Buyback Excise Tax:

The 1% excise tax on net buybacks reduced Q1 2024 operating earnings by 0.47%, up from Q4 2023’s 0.44% and up from the 0.45% for Q1 2023. The 12-month impact was 0.41%, up from 2023’s 40% and down from the proforma 2022 of 0.51%. The tax on As Reported GAAP earnings impact increased to 0.54%, up from the Q4 2023 0.50% and up from the Q1 2023 0.49%. The 12-month impact was 0.46%, up from 2023’s 0.45% and down from the proforma 2022 0.58%.

Silverblatt added: “The 1% tax remains an expense but has not impacted overall buybacks at this point. However, given the initial 1% buyback tax had bipartisan support and remains an attractive cash generator for the government, there is an expectation that some increase or potential change to the type of buybacks that are taxed will remain on the table following the election cycle. Given the current corporate sensitivity to costs, a buyback tax rate of 2%-to-2.5% was seen as impacting both buybacks and the EPS impact of share-count-reduction (which is already at a lower level due to high stock prices). This is because some of the expenditures may shift from buybacks to dividends. However, any shift would not be on a-dollar-for-dollar basis as dividends remain a long-term pure cash-flow item which must be incorporated into corporate budgets.”

Q1 2024 GICS® Sector Analysis:

Information Technology maintained its lead in buybacks, representing 24.2% of all buybacks for the quarter. Q1 2024 expenditures increased 1.8% to $57.3 billion, compared to Q4 2023’s $56.3 billion, it was up 24.8% from Q1 2023’s $45.9 billion expenditure. For the 12-months ending March 2024, the sector decreased their expenditure 11.4% to $209.3 billion, representing 25.6% of all S&P 500 buybacks, compared to $236.3 billion spent in the prior 12-month period ending March 2023, which represented 27.6% of all buybacks.

Financials increased their buybacks by 46.5% for Q1 2024 as they spent $43.1 billion on buybacks, accounting for 18.2% of all S&P 500 buybacks. This was up for the quarter compared to Q4 2023’s expenditure of $29.4 billion, but down from Q1 2023’s $46.9 billion. For the 12-month March 2024 period, Financials spent $134.5 billion, up from $113.6 billion for the prior 12-month period.

Healthcare significantly increased their Q1 2024 expenditure by 93.5%, spending $25.5 billion, compared to the Q4 2023 expenditure of $13.2 billion and up 10.0% from the Q1 2023 $23.2 billion expenditure. For the 12-months ending March 2024, the sector spent $67.1 billion, down from the prior period’s expenditure of $84.9 billion.

Consumer Staples increased their spending in Q1 2024 by 32.7% to $12.0 billion, up from the prior $9.0 billion and up 90.9% from the Q1 2023 expenditure of $6.3 billion.

Consumer Discretionary decreased their spending by 44.1% to $16.1 billion from Q4 2023’s $28.7 billion and was 12.3% lower than the $18.3 billion spent in Q1 2023.

Issues:

The five issues with the highest total buybacks for Q1 2024 were:

Apple (AAPL): continued to dominate the issue level buybacks, as it again spent the most of any issue with its Q1 2024 expenditure ranking as the 6th highest in S&P 500 history. For the quarter, the company spent $23.5 billion, up from Q4 2023’s $22.7 billion (the 10th largest in index history). Apple holds 18 of the top 20 record quarters (Meta Platforms holds #14 and QUALCOMM holds #16). For the 12-months ending March 2024, Apple spent $87.4 billion on buybacks, down from the prior 12-month period’s $91.1 billion. Over the five-year period Apple has spent $429 billion, and $664 billion over the ten-year period.Meta Platforms (META): $18.2 billion for Q1 2024, up from the $8.2 billion in Q4 2023; the 12-month expenditure was $34.6 billion versus the prior expenditure of $31.5 billion.Alphabet (GOOG/L): $15.7 billion for Q1 2024, down from $16.2 billion in Q4 2023; the 12-month expenditure was $62.6 billion versus $60.6 billion.NVIDA (NVDA): $9.5 billion for Q1 2024, up from $3.5 billion in Q4 2023; the 12-month expenditure was $21.3 billion versus $9.5 billion.Wells Fargo (WFC): $6.0 billion for Q1 2024, up from $2.4 billion in Q4 2023; the 12-month expenditure was $13.8 billion versus 2022’s $4.0 billion.

For more information about S&P Dow Jones Indices, please visit  https://www.spglobal.com/spdji/en/.

S&P Dow Jones Indices

S&P 500 proforma net buyback tax impact

TAX

TAX % OF

TAX % OF

$ BILLIONS

OPERATING

AS REPORTED

12 Mo Mar,’24

$7.44

0.41 %

0.46 %

12 Mo Mar,’23

$7.88

0.47 %

0.54 %

Q1 2024

$2.18

0.47 %

0.54 %

Q4 2023

$2.02

0.44 %

0.50 %

Q3 2023

$1.70

0.39 %

0.42 %

Q2 2023

$1.55

0.34 %

0.38 %

Q1 2023

$1.98

0.45 %

0.49 %

2023

$7.47

0.40 %

0.45 %

2022 proforma

$8.47

0.51 %

0.58 %

2021 proforma

$7.93

0.45 %

0.47 %

 

S&P Dow Jones Indices

S&P 500, $ U.S. BILLIONS

(preliminary in bold)

PERIOD

MARKET

OPERATING

AS REPORTED

DIVIDEND &

VALUE

EARNINGS

EARNINGS

DIVIDENDS

BUYBACKS

DIVIDEND 

BUYBACK 

BUYBACK 

$ BILLIONS

$ BILLIONS

$ BILLIONS

$ BILLIONS

$ BILLIONS

YIELD

YIELD

YIELD

12 Mo Mar,’24 Prelim.

$44,078

$1,808.90

$1,606.39

$593.08

$816.45

1.35 %

1.85 %

3.20 %

12 Mo Mar,’23

$34,342

$1,678.59

$1,469.32

$573.73

$857.20

1.67 %

2.50 %

4.17 %

2023

$40,039

$1,787.36

$1,610.73

$588.23

$795.16

1.47 %

1.99 %

3.46 %

2022

$32,133

$1,656.66

$1,453.43

$564.57

$922.68

1.76 %

2.87 %

4.63 %

2021

$40,356

$1,762.75

$1,675.22

$511.23

$881.72

1.27 %

2.18 %

3.45 %

2020

$31,659

$1,019.04

$784.21

$483.18

$519.76

1.53 %

1.64 %

3.17 %

2019

$26,760

$1,304.76

$1,158.22

$485.48

$728.74

1.81 %

2.72 %

4.54 %

2018

$21,027

$1,281.66

$1,119.43

$456.31

$806.41

2.17 %

3.84 %

6.01 %

3/28/2024 Prelim.

$44,078

$460.63

$400.23

$151.61

$236.82

1.35 %

1.85 %

3.20 %

12/31/2023

$40,039

$452.44

$401.16

$154.10

$219.09

1.47 %

1.99 %

3.46 %

9/30/2023

$35,938

$437.90

$399.35

$144.18

$185.62

1.61 %

2.19 %

3.81 %

6/30/2023

$37,162

$457.93

$405.66

$143.20

$174.92

1.55 %

2.19 %

3.74 %

3/31/2023

$34,342

$439.08

$404.57

$146.76

$215.53

1.67 %

2.50 %

4.17 %

12/31/2022

$32,133

$421.55

$331.50

$146.07

$211.19

1.76 %

2.87 %

4.63 %

9/30/2022

$30,119

$422.94

$373.04

$140.34

$210.84

1.83 %

3.26 %

5.09 %

6/30/2022

$31,903

$395.02

$360.21

$140.56

$219.64

1.70 %

3.15 %

4.85 %

3/31/2022

$38,288

$417.16

$388.68

$137.60

$281.01

1.37 %

2.57 %

3.94 %

12/31/2021

$40,356

$480.35

$456.72

$133.90

$270.10

1.27 %

2.18 %

3.45 %

9/30/2021

$36,538

$441.26

$420.64

$130.04

$234.64

1.37 %

2.03 %

3.40 %

6/30/2021

$36,325

$439.95

$409.02

$123.38

$198.84

1.33 %

1.68 %

3.01 %

3/31/2021

$33,619

$401.19

$388.84

$123.91

$178.13

1.43 %

1.48 %

2.91 %

12/31/2020

$31,659

$321.81

$265.00

$121.62

$130.59

1.53 %

1.64 %

3.17 %

9/30/2020

$27,868

$314.06

$273.29

$115.54

$101.79

1.75 %

2.05 %

3.80 %

6/30/2020

$25,637

$221.53

$147.44

$119.04

$88.66

1.93 %

2.52 %

4.45 %

3/31/2020

$21,424

$161.64

$98.48

$126.98

$198.72

2.31 %

3.37 %

5.68 %

 

S&P Dow Jones Indices

S&P 500 SECTOR BUYBACKS

SECTOR $ MILLIONS

Q1,’24

Q4,’23

Q1,’23

12MoMar,’24

12MoMar,’23

5-YEARS

10-YEARS

Consumer Discretionary

$16,059

$28,716

$18,301

$81,248

$84,301

$360,610

$793,279

Consumer Staples

$11,998

$9,042

$6,284

$30,318

$35,294

$157,523

$370,235

Energy

$14,157

$16,060

$19,304

$64,703

$74,534

$179,256

$275,563

Financials

$43,087

$29,418

$46,891

$134,549

$113,632

$710,002

$1,283,424

Healthcare

$25,522

$13,188

$23,194

$67,077

$84,941

$376,507

$783,092

Industrials

$16,854

$27,112

$14,239

$70,837

$71,589

$304,040

$656,239

Information Technology

$57,290

$56,283

$45,923

$209,260

$236,303

$1,135,899

$1,976,566

Materials

$5,241

$2,963

$3,773

$16,636

$24,725

$91,030

$159,612

Real Estate

$620

$243

$526

$1,787

$3,174

$11,962

$20,741

Communication Services

$45,126

$34,715

$35,797

$137,232

$126,691

$538,868

$573,389

Utilities

$868

$1,353

$1,299

$2,806

$2,018

$13,374

$21,088

TOTAL

$236,823

$219,091

$215,532

$816,454

$857,202

$3,879,073

$6,913,228

SECTOR BUYBACK MAKEUP %

Q1,’24

Q4,’23

Q1,’23

12MoMar,’24

12MoMar,’23

5-YEARS

10-YEARS

Consumer Discretionary

6.78 %

13.11 %

8.49 %

9.95 %

9.83 %

9.30 %

11.47 %

Consumer Staples

5.07 %

4.13 %

2.92 %

3.71 %

4.12 %

4.06 %

5.36 %

Energy

5.98 %

7.33 %

8.96 %

7.92 %

8.70 %

4.62 %

3.99 %

Financials

18.19 %

13.43 %

21.76 %

16.48 %

13.26 %

18.30 %

18.56 %

Healthcare

10.78 %

6.02 %

10.76 %

8.22 %

9.91 %

9.71 %

11.33 %

Industrials

7.12 %

12.37 %

6.61 %

8.68 %

8.35 %

7.84 %

9.49 %

Information Technology

24.19 %

25.69 %

21.31 %

25.63 %

27.57 %

29.28 %

28.59 %

Materials

2.21 %

1.35 %

1.75 %

2.04 %

2.88 %

2.35 %

2.31 %

Real Estate

0.26 %

0.11 %

0.24 %

0.22 %

0.37 %

0.31 %

0.30 %

Communication Services

19.05 %

15.85 %

16.61 %

16.81 %

14.78 %

13.89 %

8.29 %

Utilities

0.37 %

0.62 %

0.60 %

0.34 %

0.24 %

0.34 %

0.31 %

TOTAL

100.00 %

100.00 %

100.00 %

100.00 %

100.00 %

100.00 %

100.00 %

 

S&P Dow Jones Indices

S&P 500 20 LARGEST Q1 2024 BUYBACKS, $ MILLIONS 

Company  

Ticker

Sector

Q1 2024

Q4 2023

Q1 2023

12-Months

12-Months

5-Year

10-Year

Indicated

Buybacks

Buybacks

Buybacks

Mar,’24

Mar,’23

Buybacks

Buybacks

Dividend

$ Million

$ Million

$ Million

$ Million

$ Million

$ Million

$ Million

$ Million

Apple

AAPL

Information Technology

$23,489

$22,730

$20,012

$87,397

$91,101

$429,133

$663,869

$14,515

Meta Platforms

META

Communication Services

$18,170

$8,165

$10,374

$34,582

$31,494

$141,809

$164,319

$4,400

Alphabet

GOOGL

Communication Services

$15,696

$16,191

$14,557

$62,643

$60,553

$233,290

$255,709

$4,714

NVIDIA 

NVDA

Information Technology

$9,492

$3,500

$507

$21,301

$9,493

$36,508

$42,667

$988

Wells Fargo 

WFC

Financials

$6,001

$2,350

$4,016

$13,836

$4,031

$62,351

$124,396

$5,038

Caterpillar

CAT

Industrials

$4,455

$2,790

$400

$9,054

$3,812

$20,781

$29,856

$2,647

Microsoft 

MSFT

Information Technology

$4,213

$4,000

$5,509

$18,748

$25,298

$122,971

$191,972

$22,291

Cigna Group 

CI

Health Care

$4,022

$544

$962

$5,344

$7,201

$27,222

$32,558

$1,638

T-Mobile US

TMUS

Communication Services

$3,786

$2,213

$4,806

$12,351

$7,877

$40,747

$43,007

$1,358

UnitedHealth Group 

UNH

Health Care

$3,072

$1,500

$2,000

$9,072

$6,500

$29,820

$44,399

$7,769

CVS Health 

CVS

Health Care

$3,058

$5

$2,052

$3,199

$3,860

$9,432

$25,539

$3,347

Exxon Mobil

XOM

Energy

$3,011

$4,656

$4,340

$16,419

$17,428

$36,647

$52,781

$17,152

Thermo Fisher Scientific 

TMO

Health Care

$3,000

$0

$3,000

$3,000

$4,000

$13,358

$17,111

$603

Chevron 

CVX

Energy

$2,891

$3,397

$3,607

$13,962

$12,410

$31,483

$36,332

$11,309

JPMorgan Chase 

JPM

Financials

$2,832

$2,275

$2,690

$9,966

$3,397

$59,653

$119,209

$13,299

Visa

V

Financials

$2,767

$3,752

$2,200

$13,323

$9,967

$51,837

$82,702

$3,290

Goldman Sachs 

GS

Financials

$2,752

$1,001

$3,825

$6,068

$6,889

$28,031

$58,509

$3,587

Comcast 

CMCSA

Communication Services

$2,664

$3,521

$2,176

$11,779

$12,281

$32,746

$59,351

$4,913

Berkshire Hathaway

BRK.b

Financials

$2,562

$2,193

$4,450

$7,283

$9,124

$74,619

$77,550

$0

Bank of America 

BAC

Financials

$2,500

$811

$2,215

$4,861

$4,638

$66,181

$113,071

$6,610

Top 20   

$120,433

$85,594

$93,698

$364,188

$331,354

$1,548,619

$2,234,907

$129,470

S&P 500

$236,823

$219,091

$215,532

$816,454

$857,202

$3,879,073

$6,913,228

$617,469

Top 20 % of S&P 500

50.85 %

39.07 %

43.47 %

44.61 %

38.66 %

39.92 %

32.33 %

20.97 %

   Gross values are not adjusted for float

 

S&P Dow Jones Indices

S&P 500 Q1 2024 Buyback Report

SECTOR

DIVIDEND

BUYBACK 

COMBINED

YIELD

YIELD

YIELD

Consumer Discretionary

0.79 %

1.87 %

2.67 %

Consumer Staples

2.59 %

1.20 %

3.79 %

Energy

3.19 %

3.89 %

7.08 %

Financials

1.70 %

2.40 %

4.11 %

HealthCare

1.65 %

1.23 %

2.88 %

Industrials

1.47 %

1.92 %

3.39 %

Information Technology

0.66 %

1.46 %

2.12 %

Materials

1.86 %

1.66 %

3.52 %

Real Estate

3.70 %

0.19 %

3.88 %

Communications Services

1.13 %

4.10 %

5.23 %

Utilities

3.24 %

0.35 %

3.59 %

S&P 500

1.40 %

1.86 %

3.25 %

   Uses full values (unadjusted for float)

   Dividends based on indicated; buybacks based on the last 12-months ending Q1,’24

 

Share Count Changes

(Y/Y diluted shares used for EPS)

>=4%

<=-4%

Q1 2024

4.62 %

13.25 %

Q4 2023

3.81 %

12.63 %

Q3 2023

4.60 %

13.80 %

Q2 2023

4.22 %

16.27 %

Q1 2023

4.02 %

18.47 %

Q4 2022

5.01 %

19.44 %

Q3 2022

7.21 %

21.24 %

Q2 2022

8.42 %

19.84 %

Q1 2022

7.62 %

17.64 %

Q4 2021

10.06 %

14.89 %

Q3 2021

10.22 %

7.41 %

Q2 2021

11.02 %

5.41 %

Q1 2021

10.40 %

5.80 %

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P Dow Jones Indices has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit: https://www.spglobal.com/spdji/en/.

S&P Dow Jones Indices Media Contacts:
April Kabahar
(+1) 917 796 3121
april.kabahar@spglobal.com

Alyssa Augustyn
(+1) 773 919 4732
alyssa.augustyn@spglobal.com

S&P Dow Jones Indices Index Services:
Howard Silverblatt
Senior Index Analyst
(+1) 973 769 2306
howard.silverblatt@spglobal.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sp-500-q1-2024-buybacks-increase-8-1-from-q4-2023-12-month-expenditure-declines-4-8-from-previous-year-earnings-per-share-impact-reverses-showing-first-gain-in-five-quarters-buybacks-tax-results-in-a-0-47-reduction-in-q1-op-302174212.html

SOURCE S&P Dow Jones Indices

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Suzuki and Tata Elxsi Launch ‘SUZUKI-TATA ELXSI Offshore Development Center’

Published

10 minutes ago

on

November 18, 2024

By

Strategic Partnership to Drive Sustainable and Future-Ready Automotive Innovation

KAWASAKI, Japan and PUNE, India, Nov. 18, 2024 /PRNewswire/ — Suzuki Motor Corporation, a Japanese multinational mobility manufacturer, and Tata Elxsi, a global leader in design and technology services, today inaugurated the ‘SUZUKI-TATA ELXSI Offshore Development Center’ in Pune, India. This dedicated center will drive Suzuki’s innovations in advanced engineering, shaping the future of mobility.

Tata Elxsi will support Suzuki in its green mobility vision by aligning with Suzuki’s goals for sustainable innovation in lightweight design, safety, styling and engineering, eco-friendly materials, and advanced simulations to improve time-to-market. The partnership will also focus on next-generation powertrains and software-defined vehicles, fostering energy-efficient solutions for electric, hybrid, and alternative fuel vehicles.

At the inauguration, Suzuki’s Chief Technology Officer, Katsuhiro Kato, highlighted the importance of the center as a core component of Suzuki’s innovation strategy. “As the industry progresses in Connected, Autonomous, Shared, and Electric technologies, Suzuki must accelerate electronic and virtual development to meet evolving demands. Tata Elxsi’s expertise in advanced computing, simulation, and design digital makes them an ideal partner in bringing forward-thinking solutions to market. This strategic and long-term partnership incorporates Suzuki’s endeavor of minimising energy and enables India’s talent to actively contribute to our development efforts globally,” said Mr. Kato.

Manoj Raghavan, MD & CEO of Tata Elxsi, shared, “The inauguration of SUZUKI-TATA ELXSI Offshore Development Center marks a significant milestone in our partnership with Suzuki and our shared vision for the future of mobility. Tata Elxsi’s design-led, digital-first approach is uniquely positioned to support Suzuki’s energy minimisation and sustainability goals, advancing the future of automotive engineering with precision and responsibility. We are delighted to support Suzuki in this journey towards transformative automotive engineering.”

About Tata Elxsi

Incorporated in 1989, Tata Elxsi is amongst the world’s leading providers of design and technology services in select industries, including Automotive, Media & Telecom, Healthcare, and Transportation. Tata Elxsi works with leading OEMs and suppliers in the automotive and transportation industries for R&D, design, and product engineering services from architecture to launch and beyond. It combines domain experience across Autonomous, Electric, and Connected vehicle technologies and Software-defined vehicles (SDV). It is supported by a worldwide network of design studios, development centres, offices, and a global pool of over 13000 engineers and specialists.

For more information, visit www.tataelxsi.com.

About Suzuki

Suzuki Motor Corporation is one of Japan’s leading carmakers and a global motorcycle manufacturer. The company’s non-vehicle products include outboard motors for boats and motorized wheelchairs. It builds its lineup on its own and through numerous subsidiaries and joint ventures outside Japan. Suzuki was established in 1920 and has headquarters in Hamamatsu, Shizuoka. Toshihiro SUZUKI is President of the company.

Website: https://www.globalsuzuki.com

Logo: https://mma.prnewswire.com/media/742257/4913784/Tata_Elxsi_Logo.jpg

 

 

 

View original content:https://www.prnewswire.com/news-releases/suzuki-and-tata-elxsi-launch-suzuki-tata-elxsi-offshore-development-center-302308277.html

SOURCE Tata Elxsi

Continue Reading

Technology

New Report from Clarivate and Healthcare Executive Explores Mainland China’s Biopharma Revolution and Increasing Global Influence

Published

11 minutes ago

on

November 18, 2024

By

New report analyses Mainland China’s transformation into a global biopharma powerhouse, with key insights for international stakeholders

LONDON, Nov. 18, 2024 /CNW/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come.

Over the past decade, Mainland China’s biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. Driven by reforms, increased investment, and progressive policies, the industry has reduced approval timelines, raised regulatory standards, and improved patient access to advanced therapies. Insights from the Institute for Scientific Information™ show that China’s Gross Expenditure on Research and Development has grown 3.5 times over the past decade, outpacing growth rates in the UK and the U.S.1 These developments, combined with an evolving healthcare reimbursement system, have enabled both domestic and multinational companies to bring new therapies to market, benefiting millions of patients.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: “Mainland China’s ascent in the biopharma sector reflects the power of sustained investment and strategic reform. This report not only highlights the impressive achievements of the past decade but also underlines the far-reaching potential for Chinese biopharma companies to drive global medical innovation and enhance patient outcomes worldwide.”

Tan Yong, Vice President of China Pharmaceutical Enterprises Association and Publisher of Healthcare Executive, noted: “The pharmaceutical industry is poised for significant and transformative changes in the upcoming decade, driven by heightened competition. Rapid innovation and intense competition have reshaped market dynamics, leading to more focused and sustainable growth. The report offers the industry a glimpse of how Chinese pharmaceutical companies can prioritize innovation and international expansion in the next decade.”

Alice Zeng, Senior Solution Consultant, Life Sciences & Healthcare, Clarivate, added: “This report is an invaluable resource for global industry stakeholders. For pharma companies worldwide, it provides a timely understanding of Mainland China’s biopharma landscape, covering the opportunities for international collaboration and the potential for accelerated market entry.”

The report highlights Mainland China’s regulatory advancements, rapid drug launch growth, and expanding domestic R&D role. Key updates include the National Reimbursement Drug List (NRDL), where systematic price negotiations have cut costs by 50-60%, improving access to innovative drugs. Additionally, Mainland China’s share of global licensing and service deals has grown from 6.5% to nearly 9% since 2015, and the country now leads in publishing research and filing patents in key life sciences, underscoring its rising influence on the global industry.

Key insights in A Decade of Innovation, A Decade to Come, include:

Impactful policy reforms: How regulatory initiatives such as the Marketing Authorization Holder (MAH) system and priority review programs have streamlined approvals and bolstered R&D.Healthcare accessibility and innovation: An examination of Mainland China’s healthcare reforms, including the expansion of the NRDL and commercial health insurance, increasing access to cutting-edge therapies.Investment and R&D growth: Analysis of Mainland China’s record-breaking R&D investment, driving advancements in oncology, anti-infectives, and emerging therapeutic areas.Global Integration and market opportunities: Insights into the rise of Mainland China’s biopharma sector as a global player, including the increase in multinational collaborations and first-to-market launches.

With Mainland China’s share of first-time global drug launches growing, and as new therapeutic areas advance, A Decade of Innovation, A Decade to Come provides timely, in-depth insights for international investors, multinational pharmaceutical companies, and healthcare stakeholders who seek to understand Mainland China’s role in shaping the future of the biopharma landscape.

The A Decade of Innovation, A Decade to Come report draws on comprehensive data and tools trusted by the global life sciences community, including Cortellis Competitive Intelligence, Cortellis Regulatory Intelligence™, Disease Landscape & Forecast, Cortellis Deals Intelligence, Cortellis Clinical Trials Intelligence™, Cortellis Product Intelligence™, Real World Data and Analytics, Access and reimbursement payer studies, BioWorld™, Web of Science™ and Derwent Innovation™ among others. Compiled by Clarivate analysts using data gathered prior to August 31, 2024, this report reflects Clarivate’s commitment to supporting drug, device, and medical technology lifecycles. By combining patient journey data, therapeutic insights, and AI-driven analytics, Clarivate enables evidence-based decisions that advance human health.

To learn more about the Clarivate report, A Decade of Innovation, A Decade to Come, visit here.

About Healthcare Executive
With media as the outpost, conference as the platform, live video broadcasting as the tool, and expert pharmaceutical industry observers and recorders as the living force, Healthcare Executive (E药经理人) brings the top consensus of entrepreneurs, scientists, and investors in the pharmaceutical industry together on the one hand, and on the other hand gathers multi-dimensional and multi-level resources from the whole industry chain. We are dedicated to providing in-depth professional communication opportunities and influential solutions for the whole industry chain in their whole life cycle. In this regard, we make connections with client requirements upstream and downstream and make preparations for the overseas strategy in their international programs.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact 
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com

1 Source: Global Research Report: China’s research landscape, ISI, Clarivate

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-report-from-clarivate-and-healthcare-executive-explores-mainland-chinas-biopharma-revolution-and-increasing-global-influence-302307317.html

SOURCE Clarivate Plc

Continue Reading

Technology

Fastmarkets and Gulf Mercantile Exchange forge strategic partnership to innovate commodity risk management tools in the region

Published

11 minutes ago

on

November 18, 2024

By

LONDON, Nov. 18, 2024 /PRNewswire/ — Fastmarkets, a leading cross-commodity price-reporting agency, is excited to announce their strategic partnership with Gulf Mercantile Exchange Limited (GME). Fastmarkets and the GME have agreed a Memorandum of Understanding (MOU) to explore a strategic partnership aimed at enhancing risk management tools for the regional commodities market. This collaboration will focus on critical commodities and aims to advance commodity risk management, market transparency and educational initiatives.

The GME and Fastmarkets will explore collaboration across areas including new commodity derivatives, indices and hedging instruments tailored to meet the needs of regional markets. Additionally, the collaboration will focus on promoting education and fostering industry dialogue by organizing and co-hosting networking events, seminars and workshops on commodity trading, risk management and pricing strategies.

The region is expanding rapidly due to increased investment in infrastructure and diversification of the economy, positioning Fastmarkets as the trusted provider to deliver the essential tools and insights needed to navigate this growth effectively.

“We are excited to partner with Fastmarkets to bring innovative solutions to the regional commodities market,” chairman of GME Ahmad Sharaf said.

Fastmarkets is at the forefront of innovation, consistently delivering comprehensive solutions that address the evolving needs of the commodities industry, ensuring customers have reliable data and tools for informed decision-making. Through its commitment to regional support, Fastmarkets is driving growth and expansion, fostering a resilient commodities market that meets local demand and opens up new avenues for economic development and trade.

Raju Daswani, CEO of Fastmarkets, added: “This partnership represents a significant step forward in supporting the growth and development of the regional commodities market. We look forward to working together to achieve our shared goals and deliver value to our stakeholders.”

Find out how Fastmarkets can help you or email media@fastmarkets.com to connect with our team.

ABOUT FASTMARKETS

Fastmarkets is an industry-leading PRA and information provider for the agriculture, forest products, metals and energy transition commodities’ markets. Fastmarkets serves its customers with commodity benchmark prices and assessments, forecasts, analytics, insights, news and events. Its data is critical for customers seeking to understand and predict dynamic, sometimes opaque markets, enabling trading and risk management.
Fastmarkets is a global business with a history dating from 1865 and is built on trust and deep market expertise. It has more than 650 employees spread across several global locations including the UK, US, China, Singapore, Brazil, Bulgaria, Belgium, Ukraine and Finland.
Fastmarkets is a privately held UK-registered company owned by its shareholders and Astorg, a European private equity firm.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fastmarkets-and-gulf-mercantile-exchange-forge-strategic-partnership-to-innovate-commodity-risk-management-tools-in-the-region-302307014.html

SOURCE Fastmarkets

Continue Reading

Trending